ClinicalTrials.gg
RecruitingNCT07290595Updated Dec 23, 2025

Comparative Analysis Of Dexmedetomidine And Dexamethasone As An Adjuvant To 0.5%Ropivacaine On Onset Of Ultrasound Guided Supraclavicular Brachial Plexus Block In Patients Undergoing Upper Limb Surgeries

A Phase 2/3 interventional study of Ropivacaine + Dexmedetomidine and Ropivacaine + dexamethasone in Post Operative Analgesia, Bradycardia and Hypotension, sponsored by Sahiwal medical college sahiwal. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Sahiwal medical college sahiwal · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Registered 11 months after the study started (first participant enrolled Jan 2025, registered Dec 2025).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To compare the efficacy of dexmedetomidine and dexamethasone as an adjuvant to 0.5%ropivacaine on onset of ultrasound guided supraclavicular brachial plexus block in patients undergoing upper limb surgeries.

Ropivacaine hydrochloride, a long acting local anesthetic, is commonly used for supraclavicular block owing to its favorable safety profile especially in terms of minimal cardiotoxicity and less motor block. Dexmedetomidine, a highly selective alpha-2 adrenergic agonist, enhances the quality of supraclavicular block by providing sedation and analgesia while potentially prolonging the duration of block through hyperpolarization of nerve fibers. While, Dexamethasone, a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, prolongs duration of analgesia by reducing perineural inflammation and inhibiting nociceptive signal transmission. Supraclavicular brachial plexus block offers dense anesthesia for surgical procedures at or distal to the elbow with relatively high success rate, once described as "spinal of the arm". Moreover, supraclavicular brachial plexus block is an excellent alternative to general anesthesia in upper limb surgeries.

Read the detailed description

After preparation, patients will be randomized into two groups of 33 each, where group A will receive 28ml of 0.5%Ropivacaine + 1mcg/kg Dexmedetomidine (diluted in 2ml normal saline) and group B will receive 28ml of 0.5%Ropivacaine + 8mg Dexamethasone (2ml). Anesthetist involved in drug administration and observation will be blinded to coded drugs prepared by another anesthetist who will not be involved further in the study. A detailed history will be taken regarding mode of injury, any pre-existing disease and previous surgery followed by local examination of patient will be done to rule out any systemic disease. On shifting to the operation theatre, standard monitoring like pulse-oximeter, electrocardiogram and non-invasive blood pressure measurement will be started. Supraclavicular brachial plexus block will be performed under aseptic measures with the patient lying supine with head turned 30o toward the contralateral side. A linear 7-13 MHz ultrasonography probe (ACUSON P500, digital color doppler ultrasound Siemens Germany) will be placed in supraclavicular fossa and slightly angled towards the thorax. The brachial plexus appears as multiple hypoechoic disks just superficial and lateral to the subclavian artery. After identification of brachial plexus, the proposed puncture site will be infiltrated with 1ml of 2% lignocaine. Then, 25-gauge spinal needle will be inserted using in plane technique, from lateral to medial direction until the tip is visualized near the brachial plexus. After careful aspiration for blood, study drugs will be injected in 5ml increments to obtain uniform spread around brachial plexus. Patient will be assessed every 5 minutes till complete sensory and motor block or for 30 minutes, whichever is earlier, using three point scale with pin prick technique for sensory block and modified bromage scale for motor block. Side effects and complications of the technique and drugs will be monitored and appropriately treated. Outcome of study will be to compare the time of onset of sensory and motor block between 2 groups.

02

Conditions studied

  • Post Operative Analgesia
  • Bradycardia
  • Hypotension
  • Upper Limb Surgeries
03

In context

Bradycardia

317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.

This study's planned enrollment of 66 is below the median of 100 across 187 interventional studies indexed under Bradycardia.

Browse Bradycardia studies →

Lead sponsor

Sahiwal medical college sahiwal is the lead sponsor of 11 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria

  • Patients scheduled for upper limb surgery below mid-humerus level
  • Patients aged 18 to 70 years
  • Patients with I, II and III
  • Male and non-pregnant females Exclusion Criteria
  • Patients refusal
  • Patients with pre-existing peripheral neuropathy of the upper limb
  • Patients with the Infection at block site
  • Patients with history of ischemic heart disease
  • Patients with bleeding disorder or deranged coagulation profile
  • Patients with known history of allergy to local anaesthetic or any other drugs used
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Other
    Group A

    0.5%Ropivacaine + 1mcg/kg Dexmedetomidine

    Drug: Ropivacaine + Dexmedetomidine

  • Other
    Group B

    0.5%Ropivacaine + 8mg Dexamethasone

    Drug: Ropivacaine + dexamethasone

Interventions

  • DrugRopivacaine + Dexmedetomidine

    Drug pages: RopivacaineStudies of RopivacaineRopivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Supraclavicular brachial plexus block will be performed under aseptic measures with the patient lying supine with head turned 30 degrees toward the contralateral side. A linear 7-13 MHz ultrasonography probe (ACUSON P500, digital color doppler ultrasound Siemens Germany) will be placed in supraclavicular fossa and slightly angled towards the thorax. The brachial plexus appears as multiple hypoechoic disks just superficial and lateral to the subclavian artery. After identification of brachial plexus, the proposed puncture site will be infiltrated with 1ml of 2% lignocaine. Then, 25-gauge spinal needle will be inserted using in plane technique, from lateral to medial direction until the tip is visualized near the brachial plexus. After careful aspiration for blood, 28ml of 0.5%Ropivacaine + 1mcg/kg Dexmedetomidine (diluted in 2ml normal saline) will be injected in 5ml increments to obtain uniform spread around brachial plexus

    Also known as: Supravlavicular Brachial Plexus Block with Ropivacaine and Dexmedetomidine

  • DrugRopivacaine + dexamethasone

    Drug pages: RopivacaineStudies of RopivacaineRopivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Supraclavicular brachial plexus block will be performed under aseptic measures with the patient lying supine with head turned 30 degrees toward the contralateral side. A linear 7-13 MHz ultrasonography probe (ACUSON P500, digital color doppler ultrasound Siemens Germany) will be placed in supraclavicular fossa and slightly angled towards the thorax. The brachial plexus appears as multiple hypoechoic disks just superficial and lateral to the subclavian artery. After identification of brachial plexus, the proposed puncture site will be infiltrated with 1ml of 2% lignocaine. Then, 25-gauge spinal needle will be inserted using in plane technique, from lateral to medial direction until the tip is visualized near the brachial plexus. After careful aspiration for blood,28ml of 0.5%Ropivacaine + 8mg Dexamethasone (2ml)will be injected in 5ml increments to obtain uniform spread around brachial plexus

    Also known as: Supraclavicular Brachial Plexus Block with Ropivacaine and Dexamethasone

06

What researchers measure

Primary outcomes

  1. Post Operative Analgesia

    Onset of Sensory Block

    Time frame: from performance of Block upto 5 minutes

  2. Post Operative Analgesia

    Onset of Motor Block

    Time frame: from performance of block upto 5 minutes

07

Study locations

1 of 1 sites recruiting
  • Sahiwal Medical College, Sahiwal
    Sāhīwāl, Punjab Province 57000, Pakistan
    Recruiting
    • Dr Rao Riaz ul Haq, FCPS · Contactslmcswl@gmail.com · 0092404502470
    • Dr Maryam Maqsood, MBBS · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Data will be available on request after completion of study i.e. March 2026

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: March 2026

Access criteria: On Demand

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Feb 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 18, 2025
StartActual
Jan 13, 2025
Primary completionEst.
Feb 12, 2026
CompletionEst.
Mar 12, 2026
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07290595
Lead sponsor
Sahiwal medical college sahiwal
Responsible party
Maryam Maqsood (Post-Graduate Resident, Sahiwal medical college sahiwal) — Principal investigator
First posted
Dec 18, 2025
Start date
Jan 13, 2025
Primary completion
Feb 12, 2026 (estimated)
Completion
Mar 12, 2026 (estimated)
Last update
Dec 23, 2025

Study contacts

Dr Maryam Maqsood, MBBS
Contact
maryammaqsood448@gmail.com
00923347036271
Dr Muhammad Shahid, FCPS
Contact
shahidnishtar@gmail.com
00923336173056
Adeel Riaz, MD
study director · Sahiwal medical college sahiwal

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ropivacaine · Dexmedetomidine · Dexamethasone

Start the discussion